2-fluoro-N-hydroxy-6-iodobenzenecarboximidamide | 935431-11-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-fluoro-N-hydroxy-6-iodobenzenecarboximidamide
• 英文别名: 2-fluoro-N'-hydroxy-6-iodobenzenecarboximidamide
• CAS: 935431-11-1
• 化学式: C₇H₆FIN₂O
• 分子量: 280.04
• InChiKey: APNYDEYKUVQAPB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-fluoro-N-hydroxy-6-iodobenzenecarboximidamide 在 palladium diacetate potassium carbonate 、 三(邻甲基苯基)磷 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 5.25h， 生成
  参考文献：
  名称：

  Development of Orally Bioavailable and CNS Penetrant Biphenylaminocyclopropane Carboxamide Bradykinin B₁ Receptor Antagonists

  摘要：

  A series of biphenylaminocyclopropane carboxamide based bradykinin B-1 receptor antagonists has been developed that possesses good pharmacokinetic properties and is CNS penetrant. Discovery that the replacement of the trifluoropropionamide in the lead structure with polyhaloacetamides, particularly a trifluoroacetamide, significantly reduced P-glycoprotein mediated efflux for the series proved essential. One of these novel bradykinin B-1 antagonists (13b) also exhibited suitable pharmacokinetic properties and efficient ex vivo receptor occupancy for further development as a novel approach for the treatment of pain and inflammation.

  DOI：

  10.1021/jm061094b
• 作为产物：
  描述：

  2-氟-6-碘苯甲腈 在 盐酸羟胺 、 sodium t-butanolate 作用下， 以 乙醇 为溶剂， 反应 5.0h， 生成 2-fluoro-N-hydroxy-6-iodobenzenecarboximidamide
  参考文献：
  名称：

  Development of Orally Bioavailable and CNS Penetrant Biphenylaminocyclopropane Carboxamide Bradykinin B₁ Receptor Antagonists

  摘要：

  A series of biphenylaminocyclopropane carboxamide based bradykinin B-1 receptor antagonists has been developed that possesses good pharmacokinetic properties and is CNS penetrant. Discovery that the replacement of the trifluoropropionamide in the lead structure with polyhaloacetamides, particularly a trifluoroacetamide, significantly reduced P-glycoprotein mediated efflux for the series proved essential. One of these novel bradykinin B-1 antagonists (13b) also exhibited suitable pharmacokinetic properties and efficient ex vivo receptor occupancy for further development as a novel approach for the treatment of pain and inflammation.

  DOI：

  10.1021/jm061094b